Literature DB >> 15185859

Durability of the diagnosis of irritable bowel syndrome based on clinical criteria.

Olaitan A Adeniji1, Cody B Barnett, Jack A Di Palma.   

Abstract

Our purpose was to evaluate the durability of the diagnosis of irritable bowel syndrome (IBS) based on clinical criteria. The study population consisted of a cohort of previously published study patients evaluated for IBS between 1989 and 1992, who met the International Congress of Gastroenterology criteria for IBS. Patients were reinterviewed for cardinal features of IBS, Rome I, Rome II, and Manning criteria 10-13 years after the initial diagnosis. During the observational follow-up period, there were 75 patients, 14 males and 61 females, with a mean age of 47.5 +/- 11.3 years (SD; range, 20 to 75 years). Mean time of reinterview after initial diagnosis was 11.8 +/- 0.9 years (range, 10 to 13 years). None of the 75 patients had an abdominal condition which could have been mistaken for IBS. Other abdominal conditions diagnosed during this period included diverticulitis (five), uterine fibromyoma (three), and gallbladder disease (three). Sixty-nine patients (92%) did not consider their symptoms as resolved. Thirty-five (46.7%) had repeat structural evaluation of the colon for similar symptoms without any new diagnoses made. Twenty-six (34.7%) and 32 (42.7%) presently meet the Rome II and Rome I criteria for IBS, respectively. Clinicians are advised to use clinical criteria for a specific and durable diagnosis of IBS.

Entities:  

Mesh:

Year:  2004        PMID: 15185859     DOI: 10.1023/b:ddas.0000026300.47363.3b

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  25 in total

1.  Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation.

Authors:  S A Müller-Lissner; I Fumagalli; K D Bardhan; F Pace; E Pecher; B Nault; P Rüegg
Journal:  Aliment Pharmacol Ther       Date:  2001-10       Impact factor: 8.171

Review 2.  Irritable bowel syndrome. Diagnosis in the managed care era.

Authors:  G F Longstreth
Journal:  Dig Dis Sci       Date:  1997-06       Impact factor: 3.199

3.  Prognosis in the irritable-bowel syndrome. A prospective study.

Authors:  S L Waller; J J Misiewicz
Journal:  Lancet       Date:  1969-10-11       Impact factor: 79.321

4.  Alosetron controls bowel urgency and provides global symptom improvement in women with diarrhea-predominant irritable bowel syndrome.

Authors:  T Lembo; R A Wright; B Bagby; C Decker; S Gordon; P Jhingran; E Carter
Journal:  Am J Gastroenterol       Date:  2001-09       Impact factor: 10.864

5.  Utility of the Rome I and Rome II criteria for irritable bowel syndrome in U.S. women.

Authors:  William D Chey; Kevin Olden; Eric Carter; John Boyle; Douglas Drossman; Lin Chang
Journal:  Am J Gastroenterol       Date:  2002-11       Impact factor: 10.864

6.  Irritable bowel syndrome in women having diagnostic laparoscopy or hysterectomy. Relation to gynecologic features and outcome.

Authors:  G F Longstreth; D B Preskill; L Youkeles
Journal:  Dig Dis Sci       Date:  1990-10       Impact factor: 3.199

7.  A diagnostic score for the irritable bowel syndrome. Its value in the exclusion of organic disease.

Authors:  W Kruis; C Thieme; M Weinzierl; P Schüssler; J Holl; W Paulus
Journal:  Gastroenterology       Date:  1984-07       Impact factor: 22.682

8.  The irritable bowel syndrome: long-term prognosis and the physician-patient interaction.

Authors:  D M Owens; D K Nelson; N J Talley
Journal:  Ann Intern Med       Date:  1995-01-15       Impact factor: 25.391

9.  Does lactose maldigestion really play a role in the irritable bowel?

Authors:  B A Tolliver; M S Jackson; K L Jackson; E D Barnett; J F Chastang; J A DiPalma
Journal:  J Clin Gastroenterol       Date:  1996-07       Impact factor: 3.062

10.  Prognosis in the irritable bowel syndrome: a 5-year prospective study.

Authors:  R F Harvey; E C Mauad; A M Brown
Journal:  Lancet       Date:  1987-04-25       Impact factor: 79.321

View more
  9 in total

Review 1.  Irritable bowel syndrome.

Authors:  Antonella Spinelli
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

2.  Treatment of functional diarrhea.

Authors:  Evan S Dellon; Yehuda Ringel
Journal:  Curr Treat Options Gastroenterol       Date:  2006-07

Review 3.  Irritable bowel syndrome.

Authors:  Alexander Charles Ford; Per Olav Vandvik
Journal:  BMJ Clin Evid       Date:  2012-01-06

Review 4.  Irritable bowel syndrome.

Authors:  Alexander Charles Ford; Per Olav Vandvik
Journal:  BMJ Clin Evid       Date:  2010-01-05

Review 5.  IBS--review and what's new.

Authors:  Amy Foxx-Orenstein
Journal:  MedGenMed       Date:  2006-07-26

Review 6.  Irritable bowel syndrome: dietary interventions.

Authors:  Alexander Charles Ford; Per Olav Vandvik
Journal:  BMJ Clin Evid       Date:  2015-07-30

Review 7.  Applying case definition criteria to irritable bowel syndrome.

Authors:  Steven H Yale; A Kenneth Musana; Amy Kieke; Jennifer Hayes; Ingrid Glurich; Po-Huang Chyou
Journal:  Clin Med Res       Date:  2008-05

8.  Effects of tegaserod on bile composition and hepatic secretion in Richardson ground squirrels on an enriched cholesterol diet.

Authors:  Ronald Mathison; Eldon Shaffer; Hans-Juergen Pfannkuche; David Earnest
Journal:  Lipids Health Dis       Date:  2006-06-22       Impact factor: 3.876

9.  Prevalence of irritable bowel syndrome and health-related quality of life in adults aged 18 to 30 years in a Colombian University: an electronic survey.

Authors:  Martín Cañón; Alvaro J Ruiz; Martín Rondón; Jaime Alvarado
Journal:  Ann Gastroenterol       Date:  2016-09-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.